Download the Free Fishpond App!
Download on the App Store

Android App on Google play

Already own it?

Sell Yours
Home » Books » Science » Medicine » Oncology

Peptidomics of Cancer-Derived Enzyme Products

Volume 42 (The Enzymes)

By Tony Y. Hu (Volume editor), Fuyuhiko Tamanoi (Volume editor)

$206  
or 4 easy payments of $51.5 with What's this?
Free shipping Australia wide
Ships from UK
Order Now for Christmas with e-Gift
Rating:
 
Register or sign-in to rate and get recommendations.
Format: Hardback, 188 pages
Published In: United States, 18 October 2017
Peptidomics of Cancer-Derived Enzyme Products, Volume 42, the latest in The Enzymes series, is ideal for researchers in biochemistry, molecular and cell biology, pharmacology, and cancer, with this volume featuring high-caliber, thematic articles on the topic of peptidomics of cancer-derived enzyme products. Specific chapters cover Circulating peptidome and tumor-resident proteolysis, Colon tumor secretopeptidome, Chemoenzymatic method for glycomics, Human plasma peptidome for pancreatic cancer, Lipoproteomics and quantitative proteomics, Salivaomics: Protein markers/extracellular RNA/DNA in saliva, and Enzyme-responsive vectors for cancer therapy.

Table of Contents

1. Overview of this volume2. Circulating peptidome and tumor-resident proteolysis3. Colon tumor secretopeptidome4. Chemoenzymatic method for glycomics5. Human plasma peptidome for pancreatic cancer6. Lipoproteomics and quantitative proteomics7. Salivaomics: Protein markers/extracellular RNA/DNA in saliva8. Enzyme-responsive vectors for cancer therapy

Promotional Information

The latest volume in the ongoing The Enzymes series focuses on the analysis of enzymes for early cancer diagnosis

About the Author

Dr. Hu's research focuses on developing and validating integrated nanotechnique-based strategies for marker discovery and molecular diagnostics in peripheral blood samples to provide a translatable solution for personalized medicine. His innovations aim to fill current gaps in early detection, real-time therapy monitoring and effective prognostics. He has assembled a diverse team with backgrounds in biochemistry, mass spectrometry, nanofabrication, and biomedical engineering to answer these needs. Dr. Hu received his Ph.D. in Biomedical Engineering from the University of Texas at Austin where he focused on developing nanomaterials as biosensors for disease diagnosis. He has published more than 50 journal articles and has received five U.S. patents (issued and pending) on these subjects since his first faculty appointment in 2011. Dr. Hu has also published four nanomedicine-related book chapters, and has given more than 40 seminars and invited presentations at major international scientific conferences. His research team has a history of grants from the NCI, NIAID, NICHD and DOD and awards from the Gates, Dunn, Kostas, and Cockrell family foundations. His team has in-depth knowledge of multiplex-detection method development for sample processing, mass spectrometry, biomarker identification and validation. This background ideally positions his team for a leadership role in these fields and for optimal clinical translation of their platforms for improved and comprehensive analysis of blood-based biomarkers that have broad potential clinical applications. Fuyu Tamanoi is a biochemist who has served on the UCLA School of Medicine and UCLA College faculty since he joined the Department of Microbiology, Immunology & Molecular Genetics in 1993. He became a full professor in 1997. Since 1996, he has been a Director of Signal Transduction Program Area at Jonsson Comprehensive Cancer Center. Dr. Tamanoi earned his B.S. and M.S. in Biochemistry at the University of Tokyo. He received PhD in Molecular Biology at Nagoya University in 1977. He was a postdoctoral fellow at Harvard Medical School, where he worked on bacteriophage DNA replication. From 1980 to 1985, he was a senior staff investigator at Cold Spring Harbor Laboratory, where he worked on adenovirus DNA replication. From 1985 to 1993, he was an Assistant Professor and then Associate Professor at the University of Chicago, where he initiated studies on lipid modification of the Ras family proteins. His laboratory research centers on signal transduction and signal transduction inhibitors. He is currently exploring ways to deliver signal transduction inhibitors using nanoparticles.

EAN: 9780128126387
ISBN: 0128126388
Publisher: Academic Press Inc
Dimensions: 22.9 x 15.2 centimetres (0.45 kg)
Age Range: 15+ years
Tell a friend

Their Email:

Sell Yours

Already own this item?
Sell Yours and earn some cash. It's fast and free to list! (Learn More.)

Review this Product

BAD GOOD
 

Related Searches

 

Webmasters, Bloggers & Website Owners

You can earn a 5% commission by selling Peptidomics of Cancer-Derived Enzyme Products: Volume 42 (The Enzymes) on your website. It's easy to get started - we will give you example code. After you're set-up, your website can earn you money while you work, play or even sleep!

 

Authors/Publishers

Are you the Author/Publisher? Improve sales by submitting additional information on this title.

 

This item ships from and is sold by Fishpond World Ltd.